Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 440

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

Open access
Gainor, Justin F, Curigliano, Giuseppe, Kim, Dong-Wan, Lee, Dae Ho, Besse, Benjamin, Baik, Christina S, Doebele, Robert C, Cassier, Philippe A, Lopes, Gilberto, Tan, Daniel S W, Garralda, Elena, Paz-Ares, Luis G, Cho, Byoung Chul, Gadgeel, Shirish M, Thomas, Michael, Liu, Stephen V, Taylor, Matthew H, Mansfield, Aaron S, Zhu, Viola W, Clifford, Corinne, Zhang, Hui, Palmer, Michael, Green, Jennifer, Turner, Christopher D, Subbiah, Vivek·2021·The Lancet Oncology

Abstract

BACKGROUND Oncogenic alterations in RET have been identified in multiple tumour types, including 1-2% of non-small-cell lung cancers (NSCLCs). We aimed to assess the safety, tolerability, and antitumour activity of pralsetinib, a highly potent, oral, selective RET inhibitor, in patients with RET fusion-positive NSCLC. METHODS ARROW is a multi-cohort, open-label, phase 1/2 study done at 71 sites (community and academic cancer centres) in 13 countries (Belgium, China, France, Germany, Hong Kong, Italy, Netherlands, Singapore, South Korea, Spain, Taiwan, the UK, and the USA). Patients aged 18 years or older with locally advanced or metastatic solid tumours, including RET fusion-positive NSCLC, and an Eastern Cooperative Oncology Group performance status of 0-2 (later limited to 0-1 in a protocol amendment) were enrolled. In phase 2, patients received 400 mg once-daily oral pralsetinib, and could continue treatment until disease progression, intolerance, withdrawal of consent, or investigator decision. Phase 2 primary endpoints were overall response rate (according to Response Evaluation Criteria in Solid Tumours version 1·1 and assessed by blinded independent central review) and safety. Tumour response was assessed in patients with RET fusion-positive NSCLC and centrally adjudicated baseline measurable disease who had received platinum-based chemotherapy or were treatment-naive because they were ineligible for standard therapy. This ongoing study is registered with ClinicalTrials.gov, NCT03037385, and enrolment of patients with treatment-naive RET fusion-positive NSCLC was ongoing at the time of this interim analysis. FINDINGS Of 233 patients with RET fusion-positive NSCLC enrolled between March 17, 2017, and May 22, 2020 (data cutoff), 92 with previous platinum-based chemotherapy and 29 who were treatment-naive received pralsetinib before July 11, 2019 (efficacy enrolment cutoff); 87 previously treated patients and 27 treatment-naive patients had centrally adjudicated baseline measurable disease. Overall responses were recorded in 53 (61%; 95% CI 50-71) of 87 patients with previous platinum-based chemotherapy, including five (6%) patients with a complete response; and 19 (70%; 50-86) of 27 treatment-naive patients, including three (11%) with a complete response. In 233 patients with RET fusion-positive NSCLC, common grade 3 or worse treatment-related adverse events were neutropenia (43 patients [18%]), hypertension (26 [11%]), and anaemia (24 [10%]); there were no treatment-related deaths in this population. INTERPRETATION Pralsetinib is a new, well-tolerated, promising, once-daily oral treatment option for patients with RET fusion-positive NSCLC. FUNDING Blueprint Medicines.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(21)00247-3

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 26 references

Cited by

See all 440

Metadata

Authors
Gainor, J. F., Curigliano, G., Kim, D.-W., Lee, D. H., Besse, B., Baik, C. S., Doebele, R. C., Cassier, P. A., Lopes, G., Tan, D. S. W., Garralda, E., Paz-Ares, L. G., Cho, B. C., Gadgeel, S. M., Thomas, M., Liu, S. V., Taylor, M. H., Mansfield, A. S., Zhu, V. W., Clifford, C., Zhang, H., Palmer, M., Green, J., Turner, C. D., & Subbiah, V.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2021-07
Volume
22
Issue
7
Pages
959-969
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3172213464
Cited by
440
References
26
FWCI
47.80
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. https://app.cochat.ai/papers/10.1016/s1470-2045(21)00247-3
The paper
Gainor, J. F., Curigliano, G., Kim, D.-W., Lee, D. H., Besse, B., Baik, C. S., Doebele, R. C., Cassier, P. A., Lopes, G., Tan, D. S. W., Garralda, E., Paz-Ares, L. G., Cho, B. C., Gadgeel, S. M., Thomas, M., Liu, S. V., Taylor, M. H., Mansfield, A. S., Zhu, V. W., . . . Subbiah, V. (2021). Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(21)00247-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.